Skip to content
Late-StageResearch compound

MK‑2866 (Ostarine, Enobosarm)

Experimental SARM, the most studied of its kind; not approved as a medicine, and it can cause liver damage and suppress the body's own hormones.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

MK-2866 (Ostarine, Enobosarm) vial

Related comparisons

Ostarine vs RAD-140

DETAILED OVERVIEW

What is MK-2866 (Ostarine, Enobosarm)?

Ostarine (MK-2866, enobosarm) is an experimental compound, a selective androgen receptor modulator (SARM), meaning a non-steroid substance that acts on the receptor for male hormones. It has never been approved as a medicine, but of all SARMs it has been studied the most in people. In one study in cancer patients, fat-free body mass rose by about 1.3 kg compared with placebo. The large late-phase trials in cancer patients, however, did not reach their goal, so the developing company stopped that development.

It lowers the body's own testosterone production (by about 23% in the trial), worsens cholesterol values, and can cause hair loss and acne; cases of drug-induced liver damage have also been documented. In women it can cause masculinization, and the deepening of the voice is permanent. It must not be used in pregnancy, because it can cause masculinization of the fetus. It leaves the body slowly, so even if a side effect appears, its effect cannot be stopped quickly. It is widespread among bodybuilders, but it is banned in competitive sport all year round.

Mechanism

Non-steroidal selective AR modulator (aryl-propionamide). Strong AR agonist in muscle, moderate prostate.

Anabolic activity (Dalton 2011)

About 1.3 kg gain in lean body mass in cancer-related wasting

Half-life

~24 h (oral)

Onset

2-4 weeks

Legal status

Not approved; large trial failed in 2016; banned by WADA

Data console

Lab data

Androgenic:Anabolic~50:20 (muscle:prostate selectivity – high, better than LGD).
AR bindingNon-steroidal SARM, AR-binding affinity ~30-40% of…
Active half-life~24 h
Detection windowUrinary: 2-4 weeks Ostarine metabolites by LC-MS/MS (WADA-accredited). The most common cause of NFL/MLB suspension cases between 2015-2020.
AromatizationNO – non-steroidal, NOT a CYP19 substrate. E2 does not rise (Dalton 2011 Phase II).
HepatotoxicityModerate-high – 4+ documented hepatocellular injury case reports (Vilaca 2018 PMID 30171122). In clinical trials (Dalton 2011, Crawford 2016) ALT/AST elevation moderate (~1.5-2x normal at 3 mg). At UGL doses (20-30 mg/day) more severe. TUDCA + milk-thistle + monthly ALT/AST recommended (not strictly mandatory, but strongly suggested).

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • HPTA suppression: lowered testosterone, LH and FSH. At the clinical 3 mg/day dose Total T fell ~23% (Dalton 2011); at UGL doses (20-30 mg/day) suppression can be complete, with reduced libido and lethargy.
  • Adverse lipid profile: HDL ("good" cholesterol) drops ~20-30%, a class effect of SARMs. Longer or high-dose use shifts the cardiovascular risk profile unfavourably.
  • Hepatotoxicity (drug-induced liver injury, DILI): at least 4+ documented hepatocellular injury case reports (Vilaca 2018). In trials ALT/AST rose moderately (~1.5-2x); worse at UGL doses. Mechanism: a CYP3A4-mediated reactive metabolite (Solomon 2019).
  • Androgenic effects: hair loss (androgenic alopecia) in genetically predisposed users, plus acne. Milder than with more androgenic SARMs (e.g. RAD-140), but present.
  • Virilisation in women: at higher doses masculinisation (voice deepening, increased body hair, clitoral enlargement), which can be partly irreversible. Voice deepening is permanent.
  • Insomnia and lethargy: sleep disturbance and fatigue are commonly reported, partly secondary to HPTA suppression.
  • Slow clearance due to the long half-life (~24 h): if a side effect appears, the compound cannot be stopped quickly and effects persist for days.

Contraindications · 7

  • Pregnancy and breastfeeding: absolutely contraindicated due to the risk of fetal androgenisation and virilisation of a female fetus.
  • Pre-existing liver dysfunction or elevated liver enzymes: avoid given the documented DILI cases.
  • Concurrent alcohol use or other hepatotoxic agents (e.g. other oral SARMs, 17-alpha-alkylated steroids): cumulative liver burden.
  • Planned fatherhood / fertility window: due to HPTA suppression and reduced sperm parameters; full recovery takes 2-4 months.
  • Competitive athletes: banned by WADA year-round (S1.2 "other anabolic agents"), urine detection window 2-4 weeks. The most frequent cause of doping suspensions in 2015-2020.
  • Undiagnosed or androgen-sensitive conditions (e.g. prostate disease, hormone-sensitive tumours): avoid without medical evaluation.
  • Pre-existing dyslipidaemia or cardiovascular risk: the HDL drop further worsens the lipid profile.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about MK‑2866 (Ostarine, Enobosarm)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.